TriaGen Wealth Management’s ResMed RMD Stock Holding History

TriaGen Wealth Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,758	Closed	-$2.12M	–	196
2025 Q3	$2.12M	Sell	7,758 -7,856	-50%	-$2.15M	0.55%	59
2025 Q2	$4.03M	Buy	+15,614	New	+$3.72M	1.22%	19

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TriaGen Wealth Management's RMD Position: Q4 2025 in Review

TriaGen Wealth Management sold out of ResMed (RMD) in Q4 2025, closing a stake of 7,758 shares — an estimated $2.12M sold.

TriaGen Wealth Management first reported a position in RMD in Q2 2025 and held it in 2 quarters. The position peaked at $4.03M in Q2 2025. 945 funds tracked by Wall St. Rank hold RMD as of Q4 2025.

TriaGen Wealth Management reported no remaining ResMed position as of Q4 2025 after selling out during the quarter.
TriaGen Wealth Management sold 7,758 ResMed shares in Q4 2025, an estimated $2.12M.
TriaGen Wealth Management first reported a position in ResMed in Q2 2025 and held it in 2 quarters.
TriaGen Wealth Management's ResMed position peaked at $4.03M in Q2 2025.
945 funds tracked by Wall St. Rank held ResMed as of Q4 2025.

Based on TriaGen Wealth Management's 13F filing for Q4 2025, filed 27 Jan 2026.